Next Article in Journal
VEGF and Pleiotrophin Modulate the Immune Profile of Breast Cancer
Next Article in Special Issue
Prognostic Significance of Melanoma Differentiation and Trans-Differentiation
Previous Article in Journal
Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies
Previous Article in Special Issue
Surgery of Primary Melanomas
Cancers 2010, 2(2), 955-969; doi:10.3390/cancers2020955

Systemic Therapy of Non-Resectable Metastatic Melanoma

Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany
* Author to whom correspondence should be addressed.
Received: 8 March 2010 / Revised: 11 May 2010 / Accepted: 12 May 2010 / Published: 26 May 2010
View Full-Text   |   Download PDF [123 KB, uploaded 26 May 2010]


In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy.
Keywords: melanoma; metastatic; chemotherapy; targeted therapy; small molecules melanoma; metastatic; chemotherapy; targeted therapy; small molecules
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Orouji, A.; Goerdt, S.; Utikal, J. Systemic Therapy of Non-Resectable Metastatic Melanoma. Cancers 2010, 2, 955-969.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert